MATRIX EG (Matuzumab Treatment With ECX in Esophago-Gastric Cancer)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00215644
Recruitment Status : Completed
First Posted : September 22, 2005
Last Update Posted : November 7, 2016
Information provided by (Responsible Party):
Merck KGaA

Brief Summary:
The purpose of this study is to compare the effectiveness and safety of experimental treatment matuzumab and ECX chemotherapy, with ECX chemotherapy. Subjects invited to take part have metastatic cancer of the esophagus (gullet) or stomach.

Condition or disease Intervention/treatment Phase
Esophageal Cancer Gastric Cancer Drug: ECX Drug: Matuzumab + ECX Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 72 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized Phase II Open-label Controlled Study of EMD 72000 (Matuzumab), in Combination With the Chemotherapy Regimen ECX or the Chemotherapy Regimen ECX Alone as First-line Treatment in Subjects With Metastatic Esophago-gastric Adenocarcinoma
Study Start Date : August 2005
Actual Primary Completion Date : July 2008
Actual Study Completion Date : August 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Stomach Cancer

Arm Intervention/treatment
Active Comparator: 1 Drug: ECX
ECX given until progression of disease or unacceptable toxicity, for a maximum of 8 cycles- E= 50 mg per metre squared of Epirubicin given i.v. once every 3 weeks, C= 60 mg per metre squared of cisplatin given i.v. once every 3 weeks, X= 1250mg per metre squared divided into two oral doses of capecitabine given every day.

Experimental: 2 Drug: Matuzumab + ECX
800mg matuzumab given i.v. (into the vein) once per week until progression or unacceptable toxicity, along with intervention in Arm 1 (ECX)

Primary Outcome Measures :
  1. Response rate [ Time Frame: various timepoints measured ]

Secondary Outcome Measures :
  1. Response duration [ Time Frame: various timepoints measured ]
  2. median time to tumor progression [ Time Frame: various timepoints measured ]
  3. median survival time [ Time Frame: various timepoints measured ]
  4. safety and tolerability [ Time Frame: various timepoints measured ]
  5. QoL [ Time Frame: various timepoints measured ]
  6. protein biomarkers [ Time Frame: various timepoints measured ]
  7. immunogenicity [ Time Frame: various timepoints measured ]
  8. matuzumab peak and trough values [ Time Frame: various timepoints measured ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed gastric adenocarcinoma or adenocarcinoma of the lower third of the esophagus
  • metastatic disease
  • immunohistological evidence of EGFR expression from archived tissues
  • ECOG PS 0-1
  • at least 1 measurable lesion (modified WHO criteria)

Exclusion Criteria:

  • previous chemotherapy, unless neo-adjuvant or adjuvant therapy completed > 12 months prior to study treatment
  • radiotherapy or major surgery within 4 weeks prior to treatment
  • brain metastases
  • peripheral neuropathy or ototoxicity >/= Grade 2 (NCICTC V3)
  • abnormal ECG

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00215644

Research Site
Essen, Germany
Research Site
Hamburg, Germany
Research Site
Oldenburg, Germany
Research Site
Recklinghausen, Germany
Research Site
A Coruna, Spain
Research Site
Barcelona, Spain
Research Site
Cadiz, Spain
Research Site
Valencia, Spain
Research Site
Bern, Switzerland
Research Site
Geneva, Switzerland
Research Site
Lausanne, Switzerland
Research Site
St. Gallen, Switzerland
United Kingdom
Research Site
Northwood, Middlesex, United Kingdom
Research Site
Bournemouth, United Kingdom
Research Site
Cambridge, United Kingdom
Research Site
Chelmsford, United Kingdom
Research Site
Guildford, United Kingdom
Research Site
Leicester, United Kingdom
Research Site
London, United Kingdom
Research Site
Newcastle, United Kingdom
Research Site
Northwood, United Kingdom
Research Site
Portsmouth, United Kingdom
Sponsors and Collaborators
Merck KGaA
Principal Investigator: Professor David Cunningham, MD, FRCP The Royal Marsden Hospital, UK

Publications of Results:
Responsible Party: Merck KGaA Identifier: NCT00215644     History of Changes
Other Study ID Numbers: EMD 72000-032
First Posted: September 22, 2005    Key Record Dates
Last Update Posted: November 7, 2016
Last Verified: November 2016

Keywords provided by Merck KGaA:
EMD 72000
Metastatic Esophago-Gastric cancer

Additional relevant MeSH terms:
Stomach Neoplasms
Esophageal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Stomach Diseases
Head and Neck Neoplasms
Esophageal Diseases